AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

ETR:MDG1MediGene Stock Price, Forecast & News

€4.93
-0.03 (-0.60 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
€4.93
Now: €4.93
€5.10
50-Day Range
€4.54
MA: €5.07
€5.40
52-Week Range
€2.91
Now: €4.93
€7.61
Volume15,324 shs
Average Volume306,207 shs
Market Capitalization$121.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.
Read More
MediGene logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-89-2000330

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.51 million
Cash Flow€2.08 per share
Book Value€3.33 per share

Profitability

Miscellaneous

Employees106
Market Cap$121.09 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MDG1 News and Ratings via Email

Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter.

MediGene (ETR:MDG1) Frequently Asked Questions

How has MediGene's stock been impacted by COVID-19 (Coronavirus)?

MediGene's stock was trading at €4.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MDG1 shares have increased by 18.6% and is now trading at €4.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MediGene?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for MediGene.

What price target have analysts set for MDG1?

1 brokers have issued 12 month price objectives for MediGene's stock. Their forecasts range from €11.00 to €11.00. On average, they expect MediGene's share price to reach €11.00 in the next twelve months. This suggests a possible upside of 123.1% from the stock's current price. View analysts' price targets for MediGene.

Has MediGene been receiving favorable news coverage?

Media stories about MDG1 stock have been trending negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. MediGene earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about MediGene.

Who are some of MediGene's key competitors?

What other stocks do shareholders of MediGene own?

Who are MediGene's key executives?

MediGene's management team includes the following people:
  • Dr. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 68)
  • Dr. Dolores J. Schendel, CEO, Chief Scientific Officer & Member of Exec. Management Board
  • Dr. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 78)
  • Mr. Axel-Sven Malkomes, CFO, Chief Bus. Devel. Officer and Member of Exec. Management Board
  • Dr. Kai Pinkernell, Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board

What is MediGene's stock symbol?

MediGene trades on the ETR under the ticker symbol "MDG1."

What is MediGene's stock price today?

One share of MDG1 stock can currently be purchased for approximately €4.93.

How big of a company is MediGene?

MediGene has a market capitalization of $121.09 million and generates $10.51 million in revenue each year. MediGene employs 106 workers across the globe.

What is MediGene's official website?

The official website for MediGene is www.medigene.de.

How can I contact MediGene?

MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.